Funding Overview
Xyall, an Eindhoven-based MedTech startup pioneering automated tissue dissection solutions for molecular pathology workflows, has successfully raised €7.6 million in strategic investment to accelerate the global deployment of its innovative laboratory technologies. The funding round was spearheaded by Capricorn Partners through their Capricorn Healthtech Fund II, with continued backing from existing investors including Sioux Technologies, Brabant Development Agency (BOM), Health Investment Partners, and multiple private investors.
This significant capital injection positions Xyall to expand its market presence and transform how molecular pathology laboratories worldwide approach tissue analysis and diagnostic testing.
Bridging the Gap in Molecular Diagnostics
Guido du Pree, CEO of Xyall, highlighted a critical industry challenge: “Over the past decade, PCR and next-generation sequencing technologies have advanced rapidly. However, the critical step of selecting tumour tissue for molecular analysis has remained largely manual, subjective, and imprecise. With our fully automated tissue dissection solutions, Xyall provides the missing link between morphological and molecular diagnostics.”
The molecular pathology sector has witnessed remarkable technological progress in analysis techniques, yet the preparatory stages have lagged behind. Xyall’s innovation directly addresses this workflow bottleneck, enabling laboratories to match their tissue preparation capabilities with advanced analytical technologies.
The Manual Tissue Dissection Challenge
Traditional tissue dissection processes face multiple operational constraints. According to Xyall, current clinical practice requires pathologists to manually mark Regions of Interest (ROIs) on hematoxylin and eosin (H&E) stained slides. Laboratory technicians must then visually interpret these markings on separate dissection slides, manually scraping tissue and collecting samples for downstream molecular analysis.
This conventional workflow presents several critical limitations:
- Time-intensive processes that slow diagnostic turnaround
- Subjective assessment leading to potential variability
- Significant error risk affecting result reliability
- Cross-contamination concerns compromising sample integrity
- Scalability challenges limiting laboratory capacity
- Global technician shortage restricting operational expansion
These bottlenecks create substantial operational inefficiencies that impact both diagnostic accuracy and laboratory productivity, particularly as demand for precision medicine continues accelerating.
Xyall’s Automated Solution
Founded in 2018 by Guido du Pree and Hans van Wijngaarden, Xyall has developed comprehensive digitization and automation technologies that revolutionize tissue dissection workflows. The company’s integrated platform combines high-resolution slide imaging, precise image registration algorithms, workflow optimization software, and high-precision robotics into a unified automated system.
The Automated Tissue Dissection solution delivers multiple operational advantages:
- Accurate ROI determination through advanced imaging analysis
- Reduced technician workload enabling resource optimization
- Faster case processing improving diagnostic turnaround times
- Eliminated cross-contamination risk ensuring sample purity
- Enhanced diagnostic reliability supporting better patient outcomes
Dick Sietses, Investment Partner at Capricorn Partners, emphasized the technology’s clinical value: “Xyall enables pathology labs to operate more efficiently, and the evidence shows that it also supports more accurate diagnoses — particularly in fields like oncology where personalised treatment plans are essential.”
Product Portfolio and Capabilities
Xyall has strategically developed two complementary systems addressing different laboratory scales and throughput requirements.
Tissector High Throughput System
Launched in 2021, this flagship solution targets large molecular laboratories with high-volume diagnostic demands. The system’s specifications include:
- 1,800 slide capacity for batch processing efficiency
- 80+ slides per hour dissection throughput
- Better than 0.1 mm accuracy ensuring precision tissue selection
- 3 hours unattended operation maximizing workflow continuity
This high-throughput platform is particularly suited for major diagnostic centers, academic medical institutions, and pharmaceutical research facilities requiring maximum processing capacity.
Tissector Table Top Solution
Introduced in 2023, the compact Tissector Table Top (TT) addresses small to medium-sized laboratory needs with:
- 72 slide capacity optimized for moderate volumes
- 30+ slides per hour processing speed
- ≤ 0.1 mm precision maintaining diagnostic accuracy
- 2+ hours continuous operation supporting efficient workflows
This versatile system brings enterprise-grade automation capabilities to laboratories with more modest throughput requirements, democratizing access to advanced tissue dissection technology.
Market Impact and Global Expansion
The fresh capital will specifically support worldwide deployment of the Tissector Table Top system, which has already demonstrated strong market adoption. More than 15 molecular pathology laboratories currently utilize the technology, including tier-1 commercial facilities, academic institutions, pharmaceutical companies, and research institutes across the United States.
This funding enables Xyall to accelerate market penetration, expand geographic reach, and support growing demand for precision diagnostic capabilities. As personalized medicine continues advancing and molecular testing volumes increase globally, automated tissue dissection solutions represent critical infrastructure for modern pathology laboratories seeking to maintain diagnostic excellence while managing operational efficiency.
